These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 34711232

  • 1. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
    Vogelmeier CF, Jones PW, Kerwin EM, Boucot IH, Maltais F, Tombs L, Compton C, Lipson DA, Bjermer LH.
    Respir Res; 2021 Oct 28; 22(1):279. PubMed ID: 34711232
    [Abstract] [Full Text] [Related]

  • 2. Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
    Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F.
    Ther Adv Respir Dis; 2020 Oct 28; 14():1753466620968500. PubMed ID: 33167780
    [No Abstract] [Full Text] [Related]

  • 3. Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial.
    Maltais F, Naya IP, Vogelmeier CF, Boucot IH, Jones PW, Bjermer L, Tombs L, Compton C, Lipson DA, Kerwin EM.
    Respir Res; 2020 Oct 22; 21(1):280. PubMed ID: 33092591
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
    Zheng J, Zhong N, Newlands A, Church A, Goh AH.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct 22; 10():1753-67. PubMed ID: 26366068
    [Abstract] [Full Text] [Related]

  • 5. Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial.
    Kerwin EM, Boucot IH, Vogelmeier CF, Maltais F, Naya IP, Tombs L, Jones PW, Lipson DA, Keeley T, Bjermer L.
    Ther Adv Respir Dis; 2020 Oct 22; 14():1753466620926949. PubMed ID: 32462979
    [No Abstract] [Full Text] [Related]

  • 6. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 22; 11():971-9. PubMed ID: 27274218
    [Abstract] [Full Text] [Related]

  • 7. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 22; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
    Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF.
    Respir Res; 2019 Oct 30; 20(1):238. PubMed ID: 31666084
    [Abstract] [Full Text] [Related]

  • 9. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 30; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.
    Bjermer LH, Boucot IH, Vogelmeier CF, Maltais F, Jones PW, Tombs L, Compton C, Lipson DA, Kerwin EM.
    Adv Ther; 2021 Sep 30; 38(9):4815-4835. PubMed ID: 34347255
    [Abstract] [Full Text] [Related]

  • 11. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov 30; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 30; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 30; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 14. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol.
    Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 30; 11():1413-24. PubMed ID: 27445468
    [Abstract] [Full Text] [Related]

  • 15. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M, Nardin M, Santini G, Mores N, Radaeli A, Montuschi P.
    Ther Adv Respir Dis; 2018 Oct 30; 12():1753466618760779. PubMed ID: 29537340
    [Abstract] [Full Text] [Related]

  • 16. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD.
    Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 30; 13():203-215. PubMed ID: 29386889
    [Abstract] [Full Text] [Related]

  • 17. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 30; 14():1251-1265. PubMed ID: 31239659
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 30; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun 30; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 20. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun 30; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.